American Academy of Dermatology

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

This interview with Stephan Weidinger, MD, PhD, at AAD 2026 highlights new data on lebrikizumab

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.

During this video interview at AAD 2026, Gold touches on key points made in his session titled ‘Complications of Cosmetic Procedures.’

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

In this Q&A interview at AAD 2026, Gold highlights various tips and strategies for healing scars among patients with skin of color.

This Q&A interview with Gold at AAD 2026 highlights notable takeaways from his portion of the session titled 'Acne Boot Camp.'

This Q&A interview at AAD 2026 highlights health information technologies and AI tools used in dermatology practices.

This Q&A interview with Grant-Kels highlights takeaways from her session on managing the needs of patients in dermatology practicers who are pregnant.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Song speaks about JAK inhibitors and their safety in dermatology care settings, contextualizing previous data on adverse events.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.